The Medicines and Healthcare products Regulatory Agency (MHRA) has approved these medications following rigorous clinical trials demonstrating their efficacy in glycaemic control, with some agents (liraglutide, dulaglutide, and semaglutide) also showing cardiovascular benefits in specific populations
The list below is drawn from the FDA prescribing information for semaglutide [3] and tirzepatide [4], the 2023 Endocrine Society guideline [2], and the American Gastroenterological Association's 2022 clinical practice update on GLP-1 use in patients with gastrointestinal disease [5]
2010;52(2 Suppl 1):637 5 Luzzi R, et al
According to the company, refund processing may take up to 14 business days after the returned package is received and inspected
Gastrointestinal side effects lead some patients to discontinue treatment, and weight regain after stopping therapy is common